Target Audience
This activity has been designed to meet the educational needs of oncologists, surgeons and radiation therapists involved in the management of women with breast cancer.
Statement of Need/Program Overview
The rapidly evolving database of ongoing clinical trials and new results in metastatic breast cancer has brought to light a number of questions with regard to optimal management of patients with advanced disease. Patterns of care data indicate a clear lack of uniformity regarding the selection, sequencing, dosing and scheduling of agents. Community oncologists present challenging cases of women with metastatic breast cancer to a panel of research leaders, who will address patient selection for single-agent and combination chemotherapy, optimal sequencing of treatment, treatment of the elderly, choice of hormonal versus cytotoxic agents in ER-positive disease and management of HER2-positive patients.
Educational Objectives
Upon completion of this activity, participants should be able to:
| • |
Identify patients with metastatic breast cancer for whom single-agent versus combination therapy would be appropriate to counsel them regarding potential treatment options. |
| • |
Describe the optimal sequence of single-agent chemotherapies for patient subgroups. |
| • |
Distinguish the risk/benefit profiles of chemotherapeutic agents/regimens to determine a management algorithm for women with metastatic breast cancer. |
Faculty & Affiliations
Melody A Cobleigh, MD
Professor of Medicine and Director, Comprehensive Breast Center
Rush University Medical Center
Chicago, Illinois
Kathy D Miller, MD
Sheila D Ward Scholar of Medicine
Assistant Professor of Medicine
Department of Hematology/Oncology
Indiana University School of Medicine
Indianapolis, Indiana
Eric P Winer, MD
Director, Breast Oncology Center
Dana-Farber Cancer Institute
Associate Professor of Medicine
Harvard Medical School
Boston, Massachusetts
Community Panel & Affiliations
John Berry, MD
Medical Director, MacNeal Cancer Center
Berwyn, Illinois
Patricia J Madej, MD
Attending in Hematology/Oncology
Hinsdale Hospital
Associate Professor of Clinical Medicine
Northwestern University
Chicago, Illinois
James Lloyd Wade III, MD, FACP
Clinical Assistant Professor of Medicine, Northwestern University
Principal Investigator, Central Illinois CCOP
Director, Decatur Memorial Hospital Cancer Care Institute
President, Cancer Care Specialists of Central Illinois
Decatur, Illinois
CME Evaluation
An evaluation will be given to each participant at the conclusion of this activity.
Accreditation
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Credit Designation Statement
Research To Practice designates this educational activity for a maximum of 2.5 category 1 credits toward the AMA Physician's Recognition Award. Each physician should claim only those credits that he/she actually spent in the activity.
Educational Support
This event is supported by education grants from Roche Laboratories Inc.
Disclosure Policy
As a provider accredited by the Accreditation Council for Continuing Medical Education it is the policy of Research To Practice to require the disclosure of any significant financial interests or any other relationship the sponsor or faculty members have with the manufacturer(s) of any commercial product(s) discussed in an educational presentation. Faculty disclosures and disclosures of discussions unlabeled/unapproved uses of drugs or devices will be provided in meeting course materials.
Sponsorship Statement
Sponsored by Research To Practice.
|
